SymphonyAI Announces Enterprise AI Research Partnership with Semmelweis University Heart and Vascular Center
LOS ALTOS, Calif., July 14, 2021 — SymphonyAI, a leader in high-value enterprise AI solutions for key vertical sectors, announced the expansion of a partnership with Semmelweis University Heart and Vascular Center, a leading research institution in East-Central Europe.
Under the partnership, Semmelweis University researchers use SymphonyAI’s EurekaAI platform to detect higher cardiovascular risk and predict patient outcomes through AI-based analysis of Semmelweis’ historical patient data sets.
The EurekaAI enterprise platform finds patterns and delivers insights through a unique combination of topological data analysis (TDA) and supervised, semi-supervised, and unsupervised. It provides extensive data preparation, automated feature engineering, enrichment, segmentation, model selection and training, and exceptional auditing capabilities for transparency.
Semmelweis researchers use EurekaAI to analyze historical patient data to predict major adverse cardiac events in current patients. To do this, the researchers use EurekaAI unsupervised ML techniques to integrate conventional patient characteristic data and cardiovascular imaging features of heart structure and function into a patient similarity network. This work allows physicians to compare individual patients to similar patients to predict the likelihood of a heart attack.
A breakthrough in clinical insights
Semmelweis’ team successfully processed and analyzed vast numbers of dimensions that make patients very different from each other and similar enough in the most critical ways to predict outcomes better and make better clinical decisions.
“Patient similarity analysis is an evolving paradigm for precision medicine,” said Márton Tokodi, Ph.D. Fellow at Semmelweis University Heart and Vascular Center. “In this data analytic approach, patients are grouped based on their similarities in multiple clinical features. We expect to achieve breakthroughs in prognostication through integrating multiple features of cardiac function and developing a phenotypic network in which patients can be mapped to specific locations associated with distinct disease stages and clinical outcomes.”
“The use of patient similarity analysis enables the automated staging of cardiac disease severity, personalized prediction of prognosis, and monitoring progression or response to therapies,” said Dr. Dávid Becker, Ph.D., Deputy Director of the Heart and Vascular Center, Semmelweis University. “Thus, it can significantly improve the utilization of real-world data in the search for therapies, which will lead to enhanced real-time clinical insights and decision-making.”
Researchers will expand the use of EurekaAI to all medical research projects and patient data sets of Semmelweis University. Semmelweis is also a partner institution of the Hungarian Artificial Intelligence National Laboratory (MILAB), an umbrella project for the collaboration of all major research centers, universities, and large-scale national programs in Hungary. MILAB also funnels business needs and international research relations by leveraging the existing relationship of the partner institutions.
The EurekaAI platform delivers unsupervised, supervised, and semi-supervised machine learning capabilities, to help organizations achieve intelligence at scale. EurekaAI is the foundation of SymphonyAI’s packaged solutions designed to rapidly deliver business value in vertical sectors. Major organizations globally in industries including banking, healthcare, life sciences, retail, public sector, manufacturing, media, and telecom have deployed SymphonyAI solutions for new insights, improved business operations, and real business value.
SymphonyAI is building a leading enterprise AI company for digital transformation across the most important and resilient growth verticals, including life sciences, healthcare, retail, consumer packaged goods, financial services, manufacturing, and media. In each of these verticals, SAI businesses have many of the leading enterprises as clients. SAI is backed by a $1 billion commitment from Dr. Romesh Wadhwani, a successful entrepreneur and philanthropist. Since its founding in 2017, SymphonyAI has grown rapidly to a combined revenue run rate of more than $300 million and over 2,200 talented leaders, data scientists, and other professionals.